Viral Vector

Thermo Fisher to invest $475m into biopharma in 2020

25-Mar-2020 By Ben Hargreaves

Continuing a trend among larger CDMOs, Thermo Fisher reveals scale of investment into biopharma business and further focus on cell and gene therapy.

BIA Separations in deal to expand virus purification offering

20-Feb-2020 By Vassia Barba

In its latest deal, BIA Separations brings to market an elution method developed by the University of Zagreb, which helps preserve viruses’ integrity, infectivity, and potency.

Univercells expands its offering to meet ‘fast-growing’ gene therapy demand

19-Feb-2020 By Vassia Barba

Funding from Gamma supports the development of Univercells’ biomanufacturing platform and bioreactors, with the latter looking to expand into the fast-growing gene therapy segment.

Yposkesi doubles manufacturing footprint to meet AAVs growing demand

14-Jan-2020 By Vassia Barba

Yposkesi CDMO announces expansion to cover growing demand, strikes a deal on viral vectors production for a gene therapy development project.

Thermo Fisher expands site, boosts biologics processing offering

28-Nov-2019 By Vassia Barba

Thermo Fisher Scientific doubles the capacity of its gene therapy and viral vector processing facility in Alachua, Florida, to provide scalability to customers.

BIA Separations adds to Cornerstone vector development program

16-Oct-2019 By Vassia Barba

An expansion to BIA Separations' Cornerstone set of processing services for viral vector development adds the use of kryptonase and CIMmultus chromatography device.

BIA Separations launches purification technology for AAV production

17-Sep-2019 By Vassia Barba

BIA Separations introduces technology able to remove host-cell DNA and proteins from AAV products, aiming to accelerate clinical development of gene therapies.

Viral vector manufacturing collaboration generates ‘tangible value’

27-Jun-2019 By Vassia Barba & Maggie Lynch

Cobra and Symbiosis announce the completion of their collaboration on viral vector development and manufacturing, supported by £1.9m Innovate UK grant.